1 of 1
Story summary
- Scientists from Wageningen University & Research and Van Andel Institute developed ThermoCas9, a CRISPR variant that distinguishes tumor DNA from healthy DNA by methylation, enabling precise cutting.
- The study was published in Nature, signaling a major advance in targeted cancer therapy.
- ThermoCas9 shows promise for selective DNA cleavage, though further research must prove it can induce tumor cell death.
- Future applications may extend to other methylation-related diseases.
